Kordiamin 250 mg/ml 10 pcs ampoules solution for injections 2 ml

Collapse, asphyxia (including in newborns), shock during surgical operations and in the postoperative period, respiratory and circulatory depression in infectious diseases.

The single and daily doses, as well as the frequency of administration, are determined individually by the physician based on the indications and the patient's age.
The drug is administered subcutaneously, intramuscularly, and intravenously. Adults and children over 14 years old are prescribed 1-2 ml 1-3 times a day.
For intravenous administration, the single dose of the drug is diluted in 10 ml of 0.9% sodium chloride solution; it is administered over 1-3 minutes.
Maximum doses for adults for subcutaneous administration: single - 2 ml, daily - 6 ml.
For children, the following single doses are prescribed subcutaneously, depending on age:
Up to 1 year - 0.1 ml;
1-4 years - 0.15-0.25 ml;
5-6 years - 0.3 ml;
7-9 years - 0.5 ml;
10-14 years - 0.75 ml.
Administered 1-3 times a day.

Active ingredient: nikethamide (diethylamide of nicotinic acid) - 250 mg;
Excipients: water for injections up to 1.0 ml.

A clear colorless or slightly yellowish liquid with a characteristic odor.

Hypersensitivity to the components of the drug, epilepsy, history of seizures and predisposition to seizures, hyperthermia in children, pregnancy, breastfeeding period.

Use during pregnancy and breastfeeding
The drug is contraindicated during pregnancy and breastfeeding. If the use of nicetamide is necessary, the issue of discontinuing breastfeeding should be addressed.

Effect on the ability to drive vehicles and operate machinery
During the treatment with the medication, it is advisable to refrain from driving motor vehicles and engaging in other potentially dangerous activities that require increased attention and quick psychomotor reactions.

Immune system side effects: hypersensitivity reactions, including urticaria, angioedema, generalized papular rashes.
Nervous system side effects: restlessness, increased irritability, anxiety.
Cardiovascular side effects: arrhythmia, arterial hypertension, tachycardia.
Gastrointestinal side effects: nausea, vomiting.
Skin and subcutaneous tissue side effects: redness, facial puffiness, skin peeling, pruritus.
Skeletal muscle and connective tissue side effects: muscle twitching (starting with the circular muscles of the mouth), tremor, muscle rigidity.
General disorders and administration site reactions: hyperthermia, increased sweating, infiltration, tenderness, hyperemia, burning sensation of the skin at the injection site.

Symptoms: increased severity of dose-dependent side effects; in large doses, it may cause generalized tonic-clonic seizures, altered consciousness and respiration, apnea during seizures, and a fatal outcome cannot be ruled out.
Treatment: use of anticonvulsants, forced diuresis. If necessary - controlled ventilation.

Enhances the effects of psychostimulants, antidepressants.
Reduces the action of narcotic analgesics, hypnotics, neuroleptics, anxiolytics, anticonvulsants.
The effect of niketamide is reduced by aminosalicylic acid, opinozid, phenothiazine derivatives, and general anesthesia medications.
The pressor effect of niketamide is increased by monoamine oxidase inhibitors.
Niketamide contributes to the development of intolerance to fthivazide. The convulsive action of niketamide is enhanced by reserpine, aminazine.
Niketamide is ineffective in the context of deep anesthesia.

Has an analeptic effect. Stimulates the central nervous system: exerts an excitatory effect on the vasomotor center of the medulla oblongata (especially when this center is depressed), leading to an indirect increase in systemic arterial pressure. Excites the respiratory center due to its stimulating influence on the chemoreceptors of the carotid sinus reflex zone, resulting in an increase in the frequency and depth of respiratory movements. The drug does not have a direct stimulating effect on the heart and does not exert a direct vasoconstrictive effect.

Well absorbed by any route of administration. Undergoes rapid biotransformation in the liver, resulting in the formation of inactive metabolites, which are primarily excreted by the kidneys.